Compare NSRX & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSRX | TELA |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | Israel | United States |
| Employees | 7 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 41.3M |
| IPO Year | N/A | 2019 |
| Metric | NSRX | TELA |
|---|---|---|
| Price | $3.16 | $0.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $19.67 | $2.00 |
| AVG Volume (30 Days) | 11.0K | ★ 37.7K |
| Earning Date | 03-25-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $80,275,000.00 |
| Revenue This Year | N/A | $10.23 |
| Revenue Next Year | N/A | $14.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.84 |
| 52 Week Low | $1.98 | $0.50 |
| 52 Week High | $9.99 | $2.14 |
| Indicator | NSRX | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 44.92 | 41.91 |
| Support Level | $2.83 | $0.67 |
| Resistance Level | $3.60 | $0.95 |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 28.87 | 25.36 |
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.